R&G Pharmastudies Co.,Ltd.’s Net Profit Rose 5% in First Quarter of 2023

R&G Pharmastudies Co.,Ltd. (诺思格(北京)医药科技股份有限公司) (301333.SZ) reported a net profit of 28.7 million yuan in the first quarter of 2023, up 5% year-on-year.

Meanwhile, the company posted 160.9 million yuan in revenue, down 5.5% year-on-year.

At the end of the reporting period, it had 1.9 billion yuan in total assets and 299.2 million yuan in total liabilities, with a liability-to-asset ratio of 15.6%.